(FXH) Health Care AlphaDEX Fund - Overview
Etf: Pharmaceuticals, Biotechnology, Medical Devices, Health Services
Dividends
| Dividend Yield | 0.79% |
| Yield on Cost 5y | 0.76% |
| Yield CAGR 5y | 56.50% |
| Payout Consistency | 39.6% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 15.5% |
| Relative Tail Risk | 2.06% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.18 |
| Alpha | -6.36 |
| Character TTM | |
|---|---|
| Beta | 0.679 |
| Beta Downside | 0.632 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.65% |
| CAGR/Max DD | 0.06 |
Description: FXH Health Care AlphaDEX Fund January 25, 2026
The First Trust Health Care AlphaDEX® Fund (FXH) commits at least 90% of its net assets-including any borrowing-to securities selected from a modified equal-dollar weighted index that screens the Russell 1000® health-care constituents for stocks expected to generate alpha using the AlphaDEX® methodology.
As of Q4 2025, FXH carries an expense ratio of 0.70% and manages roughly $1.2 billion in assets, delivering a 12-month total return of about +8.4% versus the S&P 500 Health Care Index’s +6.1% over the same period. The broader health-care sector is being buoyed by a 4.2% YoY increase in U.S. health-care spending, a 7% Q4 2025 rise in biotech R&D expenditures, and demographic trends that project the 65-plus population to reach 22% of the U.S. by 2030-factors that can amplify demand for innovative medical products.
For a deeper, data-driven comparison of FXH’s risk-adjusted performance, you might explore the ValueRay platform.
What is the price of FXH shares?
Over the past week, the price has changed by -0.46%, over one month by -3.39%, over three months by +3.28% and over the past year by +5.85%.
Is FXH a buy, sell or hold?
What are the forecasts/targets for the FXH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 120.2 | 5.3% |
FXH Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 972.4m USD (972.4m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 972.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 972.4m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.42% (E(972.4m)/V(972.4m) * Re(8.42%) + (debt-free company))
Discount Rate = 8.42% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)